Parexel expands eClinical presence in China

Parexel International ($PRXL) has cut the ribbon on a facility in Shenyang, China, adding to the CRO's heft in the country and giving it a platform to expand the adoption of its eClinical offerings.

The new site joins Parexel's operations in Beijing, Chengdu, Guangzhou, Shanghai and Hong Kong, and the company will use it to serve biopharma clients in the Asia Pacific region and grow the Chinese market for its Perceptive Informatics business and the MyTrials data management platform.

"Given the globalization of clinical trials today and the continuing shift of drug development activity from West to East, China has become an important strategic destination for Parexel's clients and business," COO Mark Goldberg said in a statement. "With the opening of the Shenyang operation hub in China, Parexel commits to continuing to expand its service scope and local expertise."

Furthermore, Parexel has partnered with the Shenyang Pharmaceutical University to train graduates on clinical trial conduct, data management and pharmacovigilance, the company said, offering alumni the chance to work on regional and global studies.

Parexel said the partnership demonstrates the company's commitment to China's growing biopharma market, and Shenyang Pharmaceutical University Professor Jing-Yu Yang said Parexel's efforts will provide students with a rare opportunity.

"The collaboration will not only provide our Clinical Pharmacy students with the opportunity to learn about new drug development, but it will also create a foundation for research and cultivation of the next generation of talent," Yang said in a statement.

Parexel has been steadily building its Asia Pacific presence over the last decade, most recently launching a Perceptive Informatics customer care office in Shanghai and partnering with the Korea Drug Development Fund to develop and commercialize therapies in South Korea.

- read the announcement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.